Q-omics provides the consensus-scored HIGD2B profile across patient tissues and cancer cell-line models. HIGD2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HIGD2B is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, HIGD2B RNA expression shows 6,815 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, THCA, and STAD as cancer lineages where HIGD2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIGD2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIGD2B survival associations across molecular data types. HIGD2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIGD2B RNA expression–survival associations across cancer types. High HIGD2B expression shows unfavorable associations in COAD, KIRC, THCA and KIRP, but favorable associations in UCEC and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for HIGD2B RNA expression.
This table summarizes HIGD2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HIGD2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIGD2B shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in BRCA, BLCA and LUAD. The THCA box plot shows higher HIGD2B RNA expression in normal versus tumor tissue (log2 FC = −0.347, t-test p < 0.001).
This table shows molecular features associated with HIGD2B in patient tissues and cancer cell lines. In patient samples, HIGD2B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, HIGD2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
